Related Experiment Video
Updated: Sep 9, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
CRISPR-Cas13d-Mediated Targeting of a Context-Specific Essential Gene Enables Selective Elimination of Uveal Melanoma
Daniel Stauber1,2, Lucas Sosnick1,2, Yitong Ma1
1Department of Bioengineering, Stanford University, Stanford, CA, USA.
Abstract:
Uveal melanoma, the most common eye cancer in adults, remains limited to surgical intervention and chemotherapy, with a dismal survival rate that has not improved in over 50 years. To address this therapeutic impasse, we systematically analyzed public gene expression, RNAi, and CRISPR knockout datasets and identified RASGRP3 as an essential gene specifically for uveal melanoma. RasGRP3 is uniquely overexpressed and essential for survival in uveal melanoma cells, but dispensable in healthy cells. RasGRP3 remains "undruggable" due to its intracellular localization and lack of targetable binding pockets. To overcome this, we developed a CRISPR-Cas13d RNA-targeting therapeutic that specifically knocks down RasGRP3 mRNA. This Cas13d-based therapeutic mediates selective uveal melanoma killing through two synergistic mechanisms: (i) direct silencing of the essential RasGRP3 transcript, and (ii) collateral RNA degradation triggered by the cleavage of overexpressed RasGRP3. When delivered via optimized lipid nanoparticles encoding Cas13d mRNA and guide RNA, this strategy eliminated >97% of uveal melanoma cells while sparing healthy cells, including retinal pigment epithelial cells. This approach outperformed conventional Cas9 and siRNA methods in potency without inducing permanent genomic alterations. Our findings establish a RNA-targeting therapeutic for uveal melanoma and a framework for Cas13d-based interventions against broad "undruggable" cancers.
Insights
Researchers developed a novel RNA-targeting therapy using CRISPR-Cas13d to silence the essential RASGRP3 gene in uveal melanoma. This breakthrough offers a potent new treatment for this aggressive eye cancer, significantly improving survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Uveal melanoma is the most common adult eye cancer with limited treatment options and poor survival rates.
- Existing therapies like surgery and chemotherapy have shown minimal improvement over 50 years.
- RASGRP3 is identified as a key gene essential for uveal melanoma survival but not in healthy cells.
Purpose of the Study:
- To develop a novel therapeutic strategy for uveal melanoma targeting the undruggable RASGRP3.
- To investigate the efficacy of a CRISPR-Cas13d RNA-targeting system against uveal melanoma.
- To establish a framework for using Cas13d-based therapies against other difficult-to-treat cancers.
Main Methods:
- Systematic analysis of public gene expression, RNAi, and CRISPR knockout datasets.
- Development of a CRISPR-Cas13d RNA-targeting therapeutic to knockdown RASGRP3 mRNA.
- Delivery of Cas13d mRNA and guide RNA via optimized lipid nanoparticles.
Main Results:
- The CRISPR-Cas13d therapeutic selectively eliminated over 97% of uveal melanoma cells.
- The therapy works through synergistic mechanisms: direct RASGRP3 silencing and collateral RNA degradation.
- This approach demonstrated superior potency compared to Cas9 and siRNA without causing genomic alterations.
Conclusions:
- A novel RNA-targeting therapeutic using CRISPR-Cas13d is established for uveal melanoma.
- This strategy effectively targets the previously undruggable RASGRP3 gene.
- The findings provide a foundation for developing Cas13d-based treatments for various cancers.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
01:59CRISPR
01:16In-vitro Mutagenesis